Ira Kalfus, MD, has over 15 years of experience in drug development and 30 years of experience in medicine. Previously, he was at Thar Pharmaceutics where he led the clinical development of T121 before Thar’s acquisition by Grünenthal GmbH. He was also a Medical Director at Redhill Therapeutics where he led the clinical development and FDA approval of Talicia® which is now being commercially launched. Previously, he was the VP of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze®, which was approved by the FDA. Lev was acquired by ViroPharma in a deal valued at $618 million. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine (MD) and Columbia University (BA in Biology).